その他

Tohoku Community Cancer Services Program地域がん医療推進センター

  • がん教育
  • がんゲノム
  • 地域医療

STAFF

Professor

  • Shirota, HidekazuAssociate Professor. 城田 英和 准教授

CONTACT

TEL:+81-22-717-7087
E-MAIL:ganpro*med.tohoku.ac.jp
(「*」を「@」に変換してください)

OUTLINE

Our department was established for the purpose of exchanging human resources among medical specialists, providing the latest diagnostic techniques such as clinical trials and genetic diagnosis, and promoting a system for patient groups, cancer consultation, and palliative care networks. If the characteristics and problems of cancer care in Miyagi Prefecture was considered, it can be illustrated a microcosm of Japan as a whole, with its aging society and the concentration of cancer care resources in urban areas. Thus, by using Miyagi Prefecture as a model for regenerating regional cancer care, it may be possible to find a way to solve the problems of cancer care in Japan as a whole. We believe that the establishment of this department at Tohoku University and the development and formation of human and intellectual networks with local medical institutions are meaningful.

専門医療人の人材交流、臨床試験や遺伝子診断などの最新の診断技術の提供、患者会・がん相談・緩和医療のネットワークの体制を整備・推進する目的で地域がん医療推進センターが設立されました。宮城県のがん医療の特徴・問題点を検討していくと、高齢化社会、がん医療資源の都市部集中など、まさに日本全体の縮図と言えるのではないでしょうか。このように宮城県をモデルとして、地域がん医療の再生を図ることで、日本全体のがん医療の問題を解決する方策を見出すことが可能かもしれません。東北大学に地域がん医療推進センターを設置し、地域医療機関との間で人的・知的ネットワークを開発・形成することは、このような点から意義のあることと考え、活動を続けております。

ARTICLE

Ito S E,Shirota H,et al. IL-4 blockade alters the tumor microenvironment and augments the response to cancer immunotherapy in a mouse model. Cancer Immunol Immunother. 66(11): 1485-1496, 2017

Shirota H,et al. IL4 from T Follicular Helper Cells Downregulates Antitumor Immunity. Cancer Immunol Res. 5(1):61-71, 2017

Shirota H and Klinman DM. Chapter 9 “CpG ODN as adjuvants for clinical use”, p.163-198. Immunopotentiators in Modern Vaccines Second Edition, edited by Dr. Virgil Schijns and Dr. Derek O'Hagan. Academic Press/Elsevier, UK/USA, 2017

Shirota H,Klinman D M. Recent progress concerning CpG DNA and its use as a vaccine adjuvant. Expert Rev Vaccines. 13(2): 299-312. 2014

Shirota Y,Shirota H,Klinman D M. Intratumoral injection of CpG oligonucleotides induces the differentiation and reduces the immunosuppressive activity of myeloid-derived suppressor cells. J Immunol. 188(4):1592-1599. 2012

一覧へ戻る
ページトップへ戻る